FAIRFIELD, Conn., March 5, 2014 /PRNewswire/ -- Competitive
Technologies, Inc., (OTCQX: CTTC) (CTI), names Joel Bradus, former "Big Pharma" sales
executive, U.S. division head of product sales. Mr. Bradus was
appointed with the full responsibility of steering and expanding
the Calmare products sales force in the
United States.
Mr. Bradus spent 11 years at Schering-Plough including director
level positions in institutional sales and business analysis. At
Pfizer, he led quantitative analysis for the entire product
line. Getting Dendrite started and profitable in this
country, and 900% growth at Market Measures before being named
Managing Director are just two of his accomplishments.
"Joel is the right man to grow sales," commented Competitive
Technologies President & CEO Conrad
Mir. "His expertise in pharmaceutical sales, product
strategies and sales team building will help define CTI's product
footprint in the pain management space."
Physicians interested in learning more about Calmare are
encouraged to reach out to Mr. Bradus at
jbradus@competitivetech.net.
About Mr. Bradus
After a 30+ year career supporting
the pharmaceutical industry, Mr. Bradus recently served as managing
partner of The Concierge Inc., where he has helped grow a dozen
businesses. His long record of accomplishments is split between the
manufacturer and supplier sides of the industry. He spent 11 years
at Schering including director level positions in institutional
sales and business analysis. At Pfizer, he led quantitative
analysis for the entire product line. Mr. Bradus was
responsible for getting Dendrite started and profitable in this
country with 900% growth at market measures before being named
Managing Director are just two of Joel's accomplishments. He
is frequent speaker at industry conferences and has served as
adjunct faculty at the local college. Mr. Bradus is based in
Spring Lake, NJ where he lives
with his family.
About the Company
Competitive Technologies Inc., (CTI)
is a biotechnology company developing and commercializing
innovative products and technologies. CTI is the licensed
distributor of the non-invasive Calmare® pain therapy medical
device, which incorporates the biophysical "Scrambler Therapy"®
technology developed to treat neuropathic and cancer-derived pain
by Professor Giuseppe Marineo.
Forward-Looking Statements
Certain statements
contained in this press release are forward-looking statements that
involve risks and uncertainties. The statements contained herein
that are not purely historical are forward looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements deal with the Company's current
plans, intentions, beliefs and expectations and statements of
future economic performance. Forward-looking statements
involve known and unknown risks and uncertainties that may cause
the Company's actual results in future periods to differ materially
from what is currently anticipated. Factors that could cause or
contribute to such differences include those discussed from time to
time in reports filed by the Company with the Securities and
Exchange Commission. The Company cannot guarantee its future
results, levels of activity, performance or achievements.
Contacts:
|
|
Competitive
Technologies,
Inc.
|
JV Public
Relations
|
Conrad
Mir
|
Janet
Vasquez
|
President and
CEO
|
Managing
Director
|
cmir@competitivetech.net
|
jvasquez@jvprny.com
|
973.798.8882
|
212.645.5498
|
The Calmare device is currently being
manufactured for sale by GEOMC Co., Ltd. of Seoul, South Korea.
Scrambler Therapy®:
www.scramblertherapy.org/english.htm
Calmare®: www.calmarett.com
CTI: www.competitivetech.net
SOURCE Competitive Technologies, Inc.